IN8bio, Inc.: IN8bio is focused on developing allogeneic, autologous and genetically modified gamma-delta T cells therapies for the treatment of cancers, including solid tumors. IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for both of its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma, which is a difficult to treat brain tumor that progresses rapidly, and INB-100 for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation. IN8bio’s technology incorporates drug-resistant immunotherapy (DRI), which has been shown in preclinical studies to function in combination with therapeutic levels of chemotherapy.
Sector/Industry:
Healthcare
Characteristics:
Based in...
US - Middle Atlantic
Listing
Private
Website:
Address:
79 Madison Ave.
New York, NY 10016
United States